Utah Medical Products, Inc.
UTMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.16 | 20.85 | 1.87 | 0.66 |
| FCF Yield | 6.78% | 7.07% | 5.56% | 5.66% |
| EV / EBITDA | 8.07 | 8.63 | 10.83 | 11.62 |
| Quality | ||||
| ROIC | 9.45% | 10.63% | 13.38% | 13.09% |
| Gross Margin | 59.03% | 59.81% | 61.58% | 63.03% |
| Cash Conversion Ratio | 1.07 | 1.34 | 1.28 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.86% | 0.79% | 7.42% | 1.51% |
| Free Cash Flow Growth | -32.56% | 6.46% | -1.56% | 7.13% |
| Safety | ||||
| Net Debt / EBITDA | -5.03 | -3.74 | -2.78 | -2.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.90 | 2.11 | 2.28 | 2.75 |
| Cash Conversion Cycle | 216.62 | 183.99 | 176.70 | 155.61 |